Caffeine Blues_ Wake Up to the Hidden Dangers of America's #1 Drug ( PDFDrive )
Page 37
O. Nikodijevic, K. A. Jacobson, and J. W. Daly, “Locomotor Activity in Mice During Chronic Treatment with Caffeine and Withdrawal,” Pharmacology, Biochemistry and Behavior, January 1993;44(1):199–216. (back to text) 54
L. Linde, “An Auditory Attention Task: A Note on the Processing of Verbal Information,” Perceptual and Motor Skills, April 1994;78(2):563–70. (back to text)
55
O. G. Cameron, J. G. Modell, and M. Hariharan, “Caffeine and Human Cerebral Blood Flow: A Positron Emission Tomography Study,” Life Sciences, 1990;47(13):1141–46. (back to text)
56
R. J. Matthew and W. H. Wilson, “Substance Abuse and Cerebral Blood Flow,” American Journal of Psychiatry, March 1991;148(3):292–305. (back to text)
57
A. Nehlig, J. L. Daval, and G. Debry, “Caffeine and the Central Nervous System: Mechanisms of Action, Biochemical, Metabolic and Psychostimulant Effects,” Brain Research Reviews, May–August 1992;17(2):139–70. (back to text)
58
J. C. Galduroz and E. A. Carlini, “The Effects of Long-term Administration of
Guarana on the Cognition of Normal, Elderly Volunteers,” Revista Paulista de Medicina, January–February 1996; 114(1): 1073–78. (back to text) 59
J. C. Galduroz and E. de A. Carlini, “Acute Effects of the Paulinia cupana, ‘Guarana,’ on the Cognition of Normal Volunteers,” Revista Paulista de Medicina, July–September 1994;112(3):607–11. (back to text) 60
O. M. Wolkowitz, V. I. Reus, E. Roberts et al., “Dehydroepiandrosterone (DHEA) Treatment of Depression,” Biological Psychiatry, 1997:41:311–18.
(back to text)
61
D. M. Diamond, B. J. Branch, M. Fleshner et al., “Effects of Dehydroepiandrosterone Sulfate and Stress on Hippocampal Electrophysiological Plasticity,” Annals of the New York Academy of Science, 1995;774:304–07. (back to text)
62
J. Ferri, “Under Pressure,” Tampa Tribune-Times, April 27, 1997; p. 1. (back to text)
63
S. L. Dubovsky, “Generalized Anxiety Disorder: New Concepts and Psychopharmacologic Therapies,” Journal of Clinical Psychiatry, January 1990;51 supplement:3–10. (back to text)
64
A. Koczapski, J. Paredes, C. Kogan et al., “Effects of Caffeine on Behavior of Schizophrenic Inpatiems,” Schizophrenia Bulletin, 1989:15(2)339–4. (back to text)
65
T. J. Crowley, D. Chesluk, S. Dilts et al., “Drug and Alcohol Abuse among Psychiatric Admissions—Multidrug Clinical-toxicologic Study,” Archives of General Psychiatry, 1974;30:13–20. (back to text)
66
M. Rihs, C. Muller, and P. Baumann, “Caffeine Consumption in Hospitalized Psychiatric Patients,” European Archives of Psychiatry and Clinical Neuroscience, 1996;246(2):83–92. (back to text)
67
D. C. Mackay and J. W. Rollins, “Caffeine and Caffeinism,” Journal of the Royal Naval Medical Service, Summer 1989:75(2):65–67. (back to text) 68
A. Kruger, “Chronic Psychiatric Patients’ Use of Caffeine: Pharmacological Effects and Mechanisms,” Psychological Reports, June 1996;78(pt 1):915–23.
(back to text)
69
P. B. Lucas, D. Pickar, J. Kelsoe et al., “Effects of the Acute Administration of Caffeine in Patients with Schizophrenia,” Biological Psychiatry, July 1,
1990;28(1):35–40. (back to text)
70
G. F. Searle, “The Effect of Dietary Caffeine Manipulation on Blood Caffeine, Sleep and Disturbed Behaviour,” Journal of ‘Intellectual Disability Research, August 1994;38(pt 4):383–91. (back to text)
71
J. F. Greden, “Anxiety or Caffeinism: A Diagnostic Dilemma,” American Journal of Psychiatry, 1974; 131:1089. (back to text)
72
K. Nishihara and K. Mori, “The Differences of Self-ratings of Sleep Quality Associated with Epinephrine and Wake Time During 4-Hour Sleep,” Psychiatry and Clinical Neuroscience, October 1996;50(5):277–83. (back to text) 73
M. H. Bonnet and D. L. Arand, “The Consequences of a Week of Insomnia,”
Sleep, July 1996;19(6):453–61. (back to text)
74
B. V. Reifler, “Depression, Anxiety, and Sleep Disturbances,” International Psychogeriatrics, 1996;8 supplement 3:415–18. (back to text) 75
T. Q. Miller, T. W. Smith, C. W. Turner et al., “A Meta-analytic Review of Research on Hostility and Physical Health,” Psychological Bulletin, March 1996;119(2):322–48. (back to text)
76
M. Wald, “Violent Aggressive Motorists Account for 28,000 Deaths,” New York Times News Service, July 1997. (back to text)
77
D. K. Dekker, M. J. Paley, S. M. Popkin et al., “Locomotive Engineers and Their Spouses: Coffee Consumption, Mood, and Sleep Reports,” Ergonomics, January–March 1993;36(1–3)233–38. (back to text)
78
G. V. Hughes and F. J. Boland, “The Effects of Caffeine and Nicotine Consumption on Mood and Somatic Variables in a Penitentiary Inmate Population,” Addictive Behaviors, September–October 1992;17(5):447–57.
(back to text)
79
K. Raikkonen, A. Hautanen, and L. Keltikangas-Jarvinen, “Feelings of Exhaustion, Emotional Distress, and Pituitary and Adrenocortical Hormones in Borderline Hypertension,” Journal of Hypertension, June 1996;14(6):713–18.
(back to text)
80
P. Jin, “Changes in Heart Rate, Noradrenaline, Cortisol and Mood during Tai Chi,” Journal of Psychosomatic Research, 1989;33(2):197–206. (back to text) 81
A. McGrady, M. Woerner, G. A. Bernal et al., “Effect of Biofeedback-assisted
Relaxation on Blood Pressure and Cortisol Levels in Normotensives and Hypertensives,” Journal of Behavioral Medicine, June 1987;10(3):301–10. (back to text)
82
G. A. Smith, “Caffeine Reduction as an Adjunct to Anxiety Management,”
British Journal of Clinical Psychology, 1988;27:265–66. (back to text) Chapter 5
1
American Medical News, January 27, 1992, p. 20. (back to text) 2
W. R. Lovallo, G. A. Pincomb, B. H. Sung et al., “Hypertension Risk and Caffeine’s Effect on Cardiovascular Activity during Mental Stress in Young Men,” Health Psychology, 1991;10(4):236–43. (back to text) 3
J. M. MacDougall, L. Musante, S. Castillo et al., “Smoking, Caffeine, and Stress: Effects on Blood Pressure and Heart Rate in Male and Female College Students,” Health Psychology, 1988;7(5):46l–78. (back to text) 4
J. P. Henry and J. C. Cassel, “Psychosocial Factors in Essential Hypertension: Recent Epidemiological and Animal Experimental Evidence,” American Journal of Epidemiology, 1969;90:171–200. (back to text)
5
G. A. Pincomb, W. R. Lovallo, R. B. Passey et al., “Effect of Behavior State on Caffeine’s Ability to Alter Blood Pressure,” American Journal of Cardiology, April 1, 1988;61(10):798–802. (back to text)
6
W. R. Lovallo, M. al’Absi, G. A. Pincomb et al., “Caffeine and Behavioral Stress Effects on Blood Pressure in Borderline Hypertensive Caucasian Men,”
Health Psychology, January 1996;15(1):11–17. (back to text) 7
P. J. Green and J. Suls, “The Effects of Caffeine on Ambulatory Blood Pressure, Heart Rate, and Mood in Coffee Drinkers,” Journal of Behavioral Medicine, April 1996;19(2):111–28. (back to text)
8
J. Ratliff-Crain, M. K. O’Keeffe, and A. Baum, “Cardiovascular Reactivity, Mood, and Task Performance in Deprived and Nondeprived Coffeedrinkers,”
Health Psychology, 1989;8(4):427–47. (back to text)
9
P. Smits, T. Thein, and A. van’t Laar, “Coffee and the Human Cardiovascular System,” Netherlands Journal of Medicine, 1987;31(7):36. (back to text) 10
C. R. Lake, G. Zaloga, J. Bray et al., “Transient Hypertension after Two
Phenylpropanolamine Diet Aids and the Effects of Caffeine: A Placebocontrolled Follo
w-up Study,” American Journal of ‘Medicine, April 1989;86(4):427–32. (back to text)
11
S. S. Chua and S. I. Benrimoj, “Non-prescription Sympathomimetic Agents and Hypertension,” Medical Toxicology and Adverse Drug Experience, September–October 1988;3(5):387–417. (back to text)
12
S. C. Dilsaver, N. A. Votolato, and N. E. Alessi, “Complications of Phenylpropanolamine,” American Family Physician, April 1989;39(4):201–06.
(back to text)
13
M. A. Sloan, S. J. Kittner, D. Rigamonti et al., “Occurrence of Stroke Associated with Use/Abuse of Drugs,” Neurology, September 1991;41(9):1358–64. (back to text)
14
C. R. Lake, D. B. Rosenberg, S. Gallant et al., “Phenylpropanolamine Increases Plasma Caffeine Levels,” Clinical Pharmacology and Therapeutics, June 1990;47(6):675–85. (back to text)
15
C. R. Lake, “Manic Psychosis after Coffee and Phenylpropanolamine,”
Biological Psychiatry, August 15, 1991;30(4):401–04. (back to text) 16
E. Casiglia, S. Bongiovi, C. D. Paleari et al., “Haemodynamic Effects of Coffee and Caffeine in Normal Volunteers: A Placebocontrolled Clinical Study,” Journal of Internal Medicine, June 1991;229(6):501–04. (back to text) 17
B. H. Sung, W. R. Lovallo, G. A. Pincomb et al., “Effects of Caffeine on Blood Pressure Response during Exercise in Normotensive Healthy Young Men,” American Journal of Cardiology, April 1, 1990;65(13):909–13. (back to text)
18
G. A. Pincomb, M. F. Wilson, B. H. Sung et al., “Effects of Caffeine on Pressor Regulation during Rest and Exercise in Men at Risk for Hypertension,”
American Heart Journal, October 1991;122(pt 1):1107–15. (back to text) 19
K. J. Wise, E. A. Bergman, D. J. Sherrard et al., “Interactions between Dietary Calcium and Caffeine Consumption on Calcium Metabolism in Hypertensive Humans,” American Journal of Hypertension, March 1996;9(3):223–29. (back to text)
20
J. D. Kark, Y. Friedlander, N. A. Kaufmann et al., “Coffee, Tea and Plasma Cholesterol: The Jerusalem Lipid Research Clinic Prevalence Study,” British
Medical Journal, 1985;291:699. (back to text)
21
B. R. Davis, J. D. Curb, N. O. Borhani et al., “Coffee Consumption and Serum Cholesterol in the Hypertension Detection and Follow-up Program,” American Journal of Epidemiology, July 1988;128(1):124–136. (back to text) 22
J. Tuomilehro, A. Tanskanen, P Pietinen, et al., “Coffee Consumption Is Correlated with Serum Cholesterol in Middle-aged Finnish Men and Women,”
Journal of Epidemiology and Community Health, 1987;41:237–42. (back to text) 23
O. H. Forde, S. F. Knutsen, E. Arnesen et al., “TheTromso Heart Study: Coffee Consumption and Serum Lipid Concentrations in Men with Hypercholesterolemia: A Randomized Intervention Study,” British Medical Journal, 1985;290:893–95. (back to text)
24
B. D’Avanzo, L. Santoro, A. Nobili et al., “Coffee Consumption and Serum Cholesterol,” Preventive Medicine, 1993;22:219–24. (back to text) 25
D. S. Thelle et al., “Effects of Coffee on Serum Cholesterol,” New England Journal of Medicine, 1983;308(24):1454–57. (back to text) 26
E. Arnesen, O. H. Forde, and D. S. Thelle, “Coffee and Serum Cholesterol,”
British Medical Journal, June 30, 1984;288(6435):1960. (back to text) 27
J. D. Curb, D. M. Reed, J. A. Kautz et al., “Coffee, Caffeine, and Serum Cholesterol in Japanese Men in Hawaii,” American Journal of Epidemiology, April 1986;123(4):648–55. (back to text)
28
R. E. Fried et al., “The Effect of Filtered Coffee Consumption on Plasma Lipid Levels,” Journal of the American Medical Association, 1992;267(6):811–15. (back to text)
29
M. Wei, C. A. Macera, C. A. Hornung et al., “The Impact of Changes in Coffee Consumption on Serum Cholesterol,” Journal of Clinical Epidemiology, October 1995;48(10):1189–96. (back to text)
30
H. Heckers, U. Gobel, and U. Kleppel, “End of the Coffee Mystery: Diterpene Alcohols Raise Serum Low-density Lipoprotein Cholesterol and Triglyceride Levels,” Journal of Internal Medicine, 1994;235:192–93. (back to text) 31
M. P. Weusten van der Wouw, M. B. Katan, R. Viani et al., “Identity of the Cholesterol-raising Factor from Boiled Coffee and Its Effects on Liver Function Enzymes,” Journal of lipid Research, 1994;35:721–33. (back to text)
32
P. T. Williams, P. D. Wood, K. M. Vranizan et al., “Coffee Intake and Elevated Cholesterol and Apolipoprotein B Levels in Men,” Journal of the American Medical Association, 1985;253:1407–11. (back to text) 33
P. C. Rosmarin, “Coffee and Coronary Heart Disease: A Review,” Progress in Cardiovascular Disease, 1989;32:239–5. (back to text)
34
D. J. Dobmeyer, R. A. Stine, C. V. Leier et al., “The Arrhythmogenic Effects of Caffeine in Human Beings,” New England Journal of Medicine, April 7, 1983; 308(14):814–16. (back to text)
35
R. J. Thomas, “Caffeine and Arrhythmias: What Are the Risks?” Your Patient & Fitness, 1991;5(5):6–8. (back to text)
36
M. J. Shirlow and C. D. Mathers, “A Study of Caffeine Consumption and Symptoms: Indigestion, Palpitations, Tremor, Headache and Insomnia,”
International Journal of Epidemiology, June 1985;14(2):239–8. (back to text) 37
J. S. Stamler, M. E. Goldman, J. Gomes et al., “The Effect of Stress and Fatigue on Cardiac Rhythm in Medical Interns,” Journal of Electrocardiology, October 1992;25(4):333–38. (back to text)
38
C. M. Pratt et al., “Complex Ventricular Arrhythmias Associated with the Mitral Valve Prolapse Syndrome,” American Journal of Medicine, 1986;80(4):626–32. (back to text)
39
A. M. Costa, I. G. Maia, F. Cruz Filho et al., “Relationship between Mitral Valve Prolapse and Arrhythmogenic Right Ventricular Disease,” Arquivos Brasileiros de Cardiologia, December 1996;67(6):379–83. (back to text) 40
A. Wennmalm and M. Wennmalm, “Coffee, Catecholamines and Cardiac Arrhythmia,” Clinical Physiology, June 1989;9(3):201–06. (back to text) 41
D. Rush, “Caffeine and PAT,” Hospital Practice, 1992;27(4A):35. (back to text)
42
T. Nakanishi and M. Yoshimura, “Recent Progress in Holter Electrocardiography, Focused on Heart Rate Variability” (in Japanese), Rinsho Byori, November 1993:41(11):1206–13. (back to text)
43
H. R. Hellstrom, “Coronary Artery Vasospasm: The Likely Immediated Cause of Acute Myocardial Infarction,” British Heart Journal, April 1979;41(4):426–32. (back to text)
44
H. Weiner, “Stressful Experience and Cardiorespiratory Disorders,”
Circulation, April 1991;83(4 supplement):112–8. (back to text) 45
B. T. Altura, “Type-A Behavior and Coronary Vasospasm: A Possible Role of Hypo-magnesemia,” Medical Hypothesis, July 1980;6(7):753–57. (back to text) 46
K. Tanabe, K. Noda, A. Ozasa et al., “The Relation of Physical and Mental Stress to Magnesium Deficiency in Patients with Variant Angina,” Journal of Cardiology, 1992;22(2–3):349–55. (back to text)
47
V. Legrand, M. Deliege, L. Henrard et al., “Patients with Myocardial Infarction and Normal Coronary Arteriogram,” Chest, December 1982;82(6):678–85. (back to text)
48
O. Nygard, H. Refsum, P. M. Ueland et al., “Coffee Consumption and Plasma Total Homocysteine: The Hordaland Homocysteine Study,” American Journal of Clinical Nutrition, January 1997;65(1):136–43. (back to text) 49
I. M. Graham, L. Daly, H. Refsum et al., “Plasma Homocysteine as a Risk Factor for Vascular Disease: The European Concerted Action Project,” Journal of the American Medical Association, 1997;277:1775–81. (back to text) 50
A. Tawakol, T Omland, M. Gerhard et al., “Hyperhomocyst(e)inemia is Associated with Impaired Endothelium-
dependent Vasodilation in Humans,”
Circulation, 1997;95(5):1119–21. (back to text)
51
I. M. Graham, L. Daly, H. Refsum et al., “Plasma Homocysteine as a Risk Factor for Vascular Disease: The European Concerted Action Project,” Journal of the American Medical Association, 1997;277:1775–81. (back to text) 52
O. Vaccaro, D. Ingrosso, A. Rivellese et al., “Moderate Hyperhomocysteinaemia and Retinopathy in Insulin-dependent Diabetes,”
Lancet, April 12, 1997; 349(9058):1102–03. (back to text) 53
S. Neugebauer, T. Baba, K. Kurokawa et al., “Defective Homocysteine Metabolism as a Risk Factor for Diabetic Retinopathy,” [letter], Lancet, February 15, 1997; 349(9050):473–74. (back to text)
54
R. Roubenoff, P. Dellaripa, M. R. Nadeau et al., “Abnormal Homocysteine Metabolism in Rheumatoid Arthritis,” Arthritis and Rheumation, April 1997;40(4):718–22. (back to text)